01The evidence

Every schedule comes from a clinical trial. Here it is.

incretide does not invent any protocol. Each of the three molecules you can choose is backed by a published, registered and verifiable reference trial. This page presents them as they are: design, results, limitations and regulatory status.

Full references, PubMed links
ClinicalTrials.gov identifiers (NCT)
Results presented as averages, never as promises

02How to read each file

Each file follows the same structure: the molecule and its target, the study design (who was measured, and how), the titration schedule used, the main result with its source, and the current regulatory status.

03 — PIÈCE 01 — PROGRAMME TRIUMPH

TRIUMPHNON APPROUVÉE

Rétatrutide

Molécule

Rétatrutide (LY3437943) — triple agoniste GIP / GLP-1 / glucagon

Cible(s)

GIPR · GLP-1R · GCGR

Design de l’étude

Phase 2 randomisée, en double aveugle, contrôlée contre placebo, 48 semaines, environ 340 participants (NEJM 2023) — programme de phase 3 TRIUMPH en cours (design publié, Diabetes, Obesity and Metabolism, 2026 ; résultats topline TRIUMPH-1 annoncés le 21 mai 2026).

Schéma de titration

2 → 4 → 6 → 9 → 12 mg · paliers de 4 semainesdose maximale étudiée : 12 mg/semaine

[1] Jastreboff AM et al. — Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023 · NCT04881760 PubMed

[2] Giblin MJ et al. — Design du programme de phase 3 TRIUMPH. Diabetes, Obesity and Metabolism, 2026

[3] Eli Lilly and Company — Résultats topline TRIUMPH-1, communiqué du 21 mai 2026. 2026

NON APPROUVÉE

Le rétatrutide n’est approuvé dans aucun pays à ce jour. Le schéma proposé par incretide est issu d’un protocole d’essai clinique.

04 — PIÈCE 02 — SURMOUNT-1

SURMOUNT

Tirzépatide

Molécule

Tirzépatide — double agoniste GIP / GLP-1

Cible(s)

GIPR · GLP-1R

Design de l’étude

Phase 3 randomisée, en double aveugle, contrôlée contre placebo, 72 semaines, environ 2 500 participants.

Schéma de titration

2,5 mg → +2,5 mg toutes les 4 semaines → 15 mg maxdose maximale étudiée : 15 mg/semaine

[4] Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022 · NCT04184622 PubMed

APPROUVÉE (OBÉSITÉ)

Approuvée dans plusieurs pays pour la prise en charge de l’obésité — prescription et suivi par un médecin.

05 — PIÈCE 03 — STEP-1

STEP

Sémaglutide

Molécule

Sémaglutide — agoniste du récepteur du GLP-1

Cible(s)

GLP-1R

Design de l’étude

Phase 3 randomisée, en double aveugle, contrôlée contre placebo, 68 semaines, environ 1 900 participants.

Schéma de titration

0,25 mg → paliers de 4 semaines → 2,4 mg maxdose maximale étudiée : 2,4 mg/semaine

[5] Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine, 2021 · NCT03548935 PubMed

APPROUVÉE (OBÉSITÉ)

Approuvée dans plusieurs pays pour la prise en charge de l’obésité — prescription et suivi par un médecin.

06How to read a trial

Three trials, one method.

Thousands of participants

Population averages measured under controlled conditions, with medical supervision.

Randomized and controlled

Each participant is compared to a placebo group — this is what distinguishes a trial from a testimonial.

4-week steps

The slow titration is not a cautious turn of phrase: it is the exact schedule used in the trials, designed for tolerability.

Published and registered

Peer-reviewed journals (NEJM, DOM) and public ClinicalTrials.gov registries — everything is verifiable, with a link.

These averages include participants followed in a controlled trial. Your own trajectory depends on many factors — which is why incretide displays ranges and plans decision points.

07What these studies do not say

What these trials cannot promise you.

A population average is not an individual prediction: individual results vary widely within each trial.
Trial participants were under medical supervision — which is why incretide invites you to show your protocol to a doctor.
Retatrutide is still in development: its full phase 3 data has not all been published to date.

See the full methodology and all references

Your protocol, cited section by section.

Two minutes of questionnaire. A tracking document where every line refers back to the evidence you just read.

Create my protocol Read the methodology